➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Merck
Johnson and Johnson
Express Scripts
Dow

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

Claims for Patent: 6,344,479


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,344,479
Title: Method of preventing retinopathy of prematurity in a neonate
Abstract:A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate.
Inventor(s): Van Overmeire; Bart (Antwerp, BE), Darko; Laszlo (Westport, CT)
Assignee: Farmacon-Il, LLC (Westport, CT)
Application Number:09/813,280
Patent Claims: 1. A method of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation and stimulate normal retinal development and retinal vascularity in said neonate.

2. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is a salt of a basic amino acid.

3. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is ibuprofen lysinate or ibuprofen arginate.

4. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the L-isomer.

5. The method of preventing retinopathy of prematurity defined in claim 2 wherein the ibuprofen salt of a basic amino acid is in the form of the racemate.

6. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered by intravenous, subcutaneous or intramuscular injection.

7. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a daily dosage of 1 to 20 mg based on ibuprofen content.

8. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered in a concentration of 1 to 20 mg/ml in a vehicle acceptable for injection.

9. The method of preventing retinopathy of prematurity defined in claim 1 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered to the prematurely born neonate during the first month of life.

10. The method of preventing retinopathy of prematurity defined in claim 6 wherein the water-soluble, pharmaceutically effective salt of ibuprofen is administered once a day for 3 days in respective daily doses of about 10 mg, 5 mg and 5 mg per kg of body weight and the administration may be repeated.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Moodys
Colorcon
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.